reports
WillScot Named as Presenting Sponsor of Borchetta Bourbon Music City G...
WillScot Named as Presenting Sponsor of Borchetta Bourbon Music City Grand Prix in Partnership with Penske Entertainment Corp. PHOENIX, June 26, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), North America’s leading provider of temporary space solutions, announced its support of the Borchetta Bourbon Music City Grand Prix as a presenting sponsor of the upcoming event, in partnership with Penske Entertainment Corp. Tim Boswell, President and Chief Operating Officer, commented, “As a leading provider of complete, turnkey space solutions ...
WillScot Holdings Corp: 1 director
A director at WillScot Holdings Corp bought 10,000 shares at 26.188USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
WillScot Introduces Innovative Power Solution – Solar Power by WillSco...
WillScot Introduces Innovative Power Solution – Solar Power by WillScot PHOENIX, June 04, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, announced Solar Power by WillScot, a proprietary power solution that redefines how energy is delivered —bringing clean, reliable power to virtually any site, and unlocking new possibilities for how and where people work. was designed to provide immediate energy production and battery storage wherever WillScot’s temporary space solutions are deployed. A...
VPG to Present and Host 1x1 Investor Meetings at the 15th Annual East ...
VPG to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast IDEAS Conference on June 12, 2025 in New York, NY MALVERN, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will present at the East Coast IDEAS Investor Conference on Thursday, June 12, 2025 at the Westin Times Square in New York, NY. The company’s presentation is scheduled to begin at 1:20 p.m. ET. A live and on-demand webcast of VPG’s presentation will be available to the public and can be accessed from the following lin...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthc...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025Event details:Date:...
WillScot Announces Investor Conference Schedule for June 2025
WillScot Announces Investor Conference Schedule for June 2025 PHOENIX, May 14, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that it will participate in the following investor conferences in the upcoming month: Stifel Cross Sector Insights ConferenceDate: June 3, 2025Location: Boston, Massachusetts Baird Global Consumer, Tech & Services ConferenceDate: June 4, 2025Location: New York, New York Wells Fargo Industrials & Materials ConferenceDate: June 10, 2025Location: C...
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceuti...
WillScot Announces Partnership with Penske Entertainment Corp. to Spon...
WillScot Announces Partnership with Penske Entertainment Corp. to Sponsor NTT INDYCAR SERIES, Indianapolis Motor Speedway PHOENIX, May 07, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, announced its collaboration with Penske Entertainment Corp. to become an official partner of INDYCAR and Indianapolis Motor Speedway (IMS), providing temporary turnkey space solutions including mobile offices, storage containers, climate-controlled storage, clearspan structures and perimeter solutions for...
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results...
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individual...
VPG Reports Fiscal 2025 First Quarter Results
VPG Reports Fiscal 2025 First Quarter Results MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its fiscal 2025 first quarter ended March 29, 2025. First Fiscal Quarter Highlights (comparisons are to the comparable period a year ago): Revenues of $71.7 million decreased 11.2%.Gross profit margin was 37.7%, as compared to 43.4%.Adjusted gross profit margin* was 38.3%, as compared to 43.4%.Operating margin was (0.1%), as compared to 8.6%.Adjusted o...
WillScot Reports First Quarter 2025 Results and Reaffirms 2025 Full Ye...
WillScot Reports First Quarter 2025 Results and Reaffirms 2025 Full Year Outlook PHOENIX, May 01, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced first quarter 2025 results including key performance highlights and market updates. Q1 20251, 2 Generated revenue of $560 million, gross profit margin percentage of 53.7%, net income of $43 million and diluted earnings per share of $0.23.Increased average monthly rates, inclusive of Value-Added Products ("VAPS"), for modular sp...
WillScot Declares Quarterly Cash Dividend
WillScot Declares Quarterly Cash Dividend PHOENIX, May 01, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that its Board of Directors has declared a quarterly dividend of $0.07 per common share. The cash dividend will be paid on June 18, 2025, to shareholders of record as of the close of business on June 4, 2025. About WillScot Listed on the Nasdaq stock exchange under the ticker symbol “WSC,” WillScot is the premier provider of highly innovative and turnkey space solut...
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences C...
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, Ma...
WillScot Announces Investor Conference Schedule for May 2025
WillScot Announces Investor Conference Schedule for May 2025 PHOENIX, April 24, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that it will participate in the following investor conferences in the upcoming month: Barclays Americas Select Franchise ConferenceDate: May 6, 2025Location: London, United Kingdom Oppenheimer 20th Annual Industrial Growth ConferenceDate: May 7, 2025Location: Virtual Bank of America Industrials, Transportation & Airlines Key Leaders ConferenceD...
WillScot to Announce First Quarter 2025 Results on May 1, 2025
WillScot to Announce First Quarter 2025 Results on May 1, 2025 PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it will release its first quarter 2025 financial results on May 1, 2025, after market close. The Company’s management team will host a conference call and webcast on May 1, 2025, at 5:30 p.m. EDT to discuss the Company’s results. To access the live call by phone, use the following link by clicking to obtain registration details....
Vishay Precision Group Announces Date for Its First Quarter Fiscal 202...
Vishay Precision Group Announces Date for Its First Quarter Fiscal 2025 Earnings Conference Call MALVERN, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will release its financial results for the first quarter fiscal 2025 before the opening of the market on Tuesday, May 6, 2025. Ziv Shoshani, chief executive officer, and Bill Clancy, chief financial officer, will host a conference call that day (Tuesday, May 6, 2025) at 9:00 a.m. U.S. eastern time. To access the conference call, interested pa...
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Di...
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company...
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of ...
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a...
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virt...
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference, Apri...
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Med...
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. “We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “As a highl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.